Compare · AZN vs VRNA
AZN vs VRNA
Side-by-side comparison of AstraZeneca PLC (AZN) and Verona Pharma plc (VRNA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and VRNA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $574.39B, about 1600.6x VRNA ($358.9M).
- Over the past year, AZN is up 0.4% and VRNA is up 48.4% - VRNA leads by 48.0 points.
- AZN has hit the wire 13 times in the past 4 weeks while VRNA has been quiet.
- AZN has more recent analyst coverage (25 ratings vs 11 for VRNA).
- Company
- AstraZeneca PLC
- Verona Pharma plc
- Price
- $189.03+2.05%
- $106.91+0.11%
- Market cap
- $574.39B
- $358.9M
- 1M return
- -4.16%
- +0.55%
- 1Y return
- +0.40%
- +48.38%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- 2017
- News (4w)
- 13
- 0
- Recent ratings
- 25
- 11
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Verona Pharma plc
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. Its product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 2 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. The company is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. It also focuses on developing ensifentrine for the treatment of COVID-19. Verona Pharma plc was founded in 2005 and is headquartered in London, the United Kingdom.
Latest AZN
- Pinetree Therapeutics Announces Exercise of Option to License EGFR Degrader Program by AstraZeneca
- SEC Form 6-K filed by AstraZeneca PLC
- AstraZeneca results: Q1 2026
- SEC Form 6-K filed by AstraZeneca PLC
- BREZTRI approved in the US for asthma as first and only triple therapy for patients 12 years of age and older
- SAPHNELO approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
Latest VRNA
- SEC Form EFFECT filed by Verona Pharma plc
- SEC Form SCHEDULE 13G filed by Verona Pharma plc
- Amendment: SEC Form SCHEDULE 13G/A filed by Verona Pharma plc
- Amendment: SEC Form SCHEDULE 13G/A filed by Verona Pharma plc
- SEC Form 15-12G filed by Verona Pharma plc
- General Counsel Fisher Andrew returned 1,349,887 units of Ordinary Shares to the company and converted options into 931,984 units of Ordinary Shares, closing all direct ownership in the company (SEC Form 4)
- President and CEO Zaccardelli David returned 15,461,424 units of Ordinary Shares to the company and converted options into 3,285,280 units of Ordinary Shares, closing all direct ownership in the company (SEC Form 4)
- Chief Medical Officer Rickard Kathleen A. returned 3,564,852 units of Ordinary Shares to the company and converted options into 1,131,984 units of Ordinary Shares, closing all direct ownership in the company (SEC Form 4)
- Chief Financial Officer Hahn Mark W returned 14,550,248 units of Ordinary Shares to the company and converted options into 3,285,280 units of Ordinary Shares, closing all direct ownership in the company (SEC Form 4)
- Director Austwick Michael returned 84,712 units of Ordinary Shares to the company and converted options into 72,000 units of Ordinary Shares, closing all direct ownership in the company (SEC Form 4)